Glenn Batchelder has been appointed president and CEO and a member of the board of directors of Acceleron Pharma (Cambridge, MA, USA). Mr. Batchelder has served at Millennium Pharmaceuticals for the past five years, most recently as senior vice president of operations. Acceleron has also announced that Richard Pops, CEO of Alkermes, has joined the company's board of directors.

Vernalis (Winnersh, UK) has named Allan Baxter as a nonexecutive director. Dr. Baxter is currently senior vice president, drug discovery at GlaxoSmithKline.

Incara Pharmaceuticals (Research Triangle Park, NC, USA) has announced James D. Crapo as the company's CEO. Since 1996, Dr. Crapo has been chairman of the department of medicine and executive vice president of academic affairs at the National Jewish Medical and Research Center. He was also previously at Duke University Medical Center, where he served for 17 years as the chief of the pulmonary and critical care medicine division.

CyDex (Lenexa, KS, USA) has named Joseph A. Fix as president and COO. Dr. Fix was most recently executive vice president and COO of the NanoSystems unit of Elan.

The Global Alliance for TB Drug Development (New York), a public-private partnership to accelerate the discovery and development of more effective and affordable tuberculosis medicines, has named Ann Ginsberg head of clinical development. Dr. Ginsberg was director for project management at Merck & Co. for the past two years. Dr. Ginsberg also previously served as chief of respiratory diseases at the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health.

Dendreon (Seattle, WA, USA) has announced the retirement of chairman of the board Christopher S. Henney. Dr. Henney founded ICOS and served as its executive vice president, scientific director and director from 1989 to 1995. He also cofounded Immunex, where from 1981 to 1989, he held various positions, including director, vice chairman and scientific director. He was CEO of Dendreon from 1995 to 2002, and was president from 1998 to 2000. Current Dendreon board member Richard B. Brewer will succeed Dr. Henney as chairman.

Edward Kenney has been named executive vice president and chief business officer at Onyx Pharmaceuticals (Richmond, CA, USA), a newly created position. He joins the company from Cell Therapeutics, where he held the position of executive vice president and COO.

Symphogen (Copenhagen, Denmark) has appointed Laurence Jay Korn to its board of directors. Dr. Korn is a cofounder, chairman of the board and former CEO of Protein Design Labs.

Christof Marre has been named vice president of marketing at Corixa (Seattle, WA, USA). Mr. Marre was previously marketing director for the US oncology division at Bristol-Myers Squibb.

Avinash Nangia has been named vice president of research and development at Spherics (Lincoln, RI, USA). Dr. Nangia has more than 13 years of drug delivery experience, most recently serving as director of research and development at Andrx Pharmaceuticals.

Vaxin (Birmingham, AL, USA) has appointed David F. Novack vice president of business development and Deborah A. Schueren has joined the company as CFO on a part-time consulting basis. Mr. Novack was most recently senior director, supply chain operations with MedImmune, and Ms. Schueren previously founded and led publicly traded vaccine company Epimmune.

William W. Sims has joined Perlegen Sciences (Mountain View, CA, USA) as CFO. Mr. Sims previously served as in the same capacity for Clontech Laboratories, where he worked to prepare the company for an initial public offering. Following Clontech's acquisition by Becton Dickinson, he served as vice president of finance and business operations. In addition, Perlegen has named Russell M. Singleton as vice president, engineering and informatics. Dr. Singleton held several leadership roles at KLA-Tencor, and led the instrumentation and software development programs at Molecular Dynamics. More recently, he has led his own business and marketing strategies firm.

Peter G. Tombros has agreed to join the board of directors of Paradigm Genetics (Research Triangle Park, NC, USA). Mr. Tombros is chairman and CEO of VivoQuest. From 1994 to 2001, he served as president and CEO of Enzon, and was previously president of corporate strategic planning at Pfizer.